Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Praulent

- PMLiVE

ADA: Sanofi shifts focus to embrace integration in diabetes

Pascale Witz unveils company's ambitions at ADA conference

Gilead Sciences

Sovaldi stumbles as NICE assesses hep C drug’s price

Gilead must provide much more cost-effectiveness information

- PMLiVE

Sanofi and Medtronic to develop drug-device combos in diabetes

Companies tell PMLiVE their new alliance will take an ‘open innovation’ approach

AbbVie closes in on US approval of all-oral hepatitis C regimen

FDA grants priority review to company’s protease inhibitor ABT-450 regimen

- PMLiVE

Sanofi US takes to Pinterest for more visual sharing

Adds the online pin board to its social media toolkit

- PMLiVE

Merck agrees $3.85bn deal for hepatitis specialist Idenix

Opens up direct challenge to Gilead

- PMLiVE

Bayer’s CEO Dekkers to step down

And Sanofi CEO to move to US

- PMLiVE

Bruno Strigini leaves Merck & Co for Novartis

Will head up an oncology business boosted by the acquisition of GSK's portfolio

- PMLiVE

AbbVie, Astellas and Roche teams among Communiqué finalists

2014 shortlist also includes MHP, Pegasus, Red Door, Ruder Finn and Virgo

- PMLiVE

Hepatitis C therapies: dawn of a new age

New treatments from the likes of Merck & Co, Janssen and Gilead offer significant treatment advances

- PMLiVE

Sanofi plans OTC version of Lilly’s Cialis

Deal could see erectile dysfunction drug become available without a prescription once its patents expire

National Institute for Health and Care Excellence NICE logo

NICE backs reimbursement of Sanofi’s MS drug Lemtrada

Final guidance opens doors for use on NHS in England and Wales

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links